Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Hormonal Therapy after Pertuzumab and Trastuzumab for the Treatment of Hormone Receptor Positive, HER2 Positive Breast Cancer, the ADEPT study
Breast
Breast
This phase II trial studies the effect of hormonal therapy given after (adjuvant) combination pertuzumab/trastuzumab in treating patients with hormone receptor positive, HER2 positive breast cancer. The drugs trastuzumab and pertuzumab are both monoclonal antibodies, which are disease-fighting proteins made by cloned immune cells. Estrogen can cause the growth of breast cancer cells. Hormonal therapy, such as letrozole, anastrozole, exemestane, and tamoxifen, block the use of estrogen by the tumor cells. Giving hormonal therapy after pertuzumab and trastuzumab may kill any remaining tumor cells in patients with breast cancer.
Breast
II
Abramson, Vandana
NCT04569747
VICCBRE2243
Avelumab with Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients with Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Breast
Breast
This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope that this induction will improve the response to immunotherapy with avelumab. One treatment, sacituzumab govitecan, is a monoclonal antibody called sacituzumab linked to a chemotherapy drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as TROP2 receptors, and delivers SN-38 to kill them. Another treatment, liposomal doxorubicin, is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin, and may enhance factors associated with immune response. The third medication is called binimetinib, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may help activate the immune system. It is not yet known whether giving avelumab in combination with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan will work better in treating patients with triple negative breast cancer.
Breast
II
Abramson, Vandana
NCT03971409
VICCBRE1987
Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
Breast
Breast
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. The usual approach for patients with early-stage TNBC who receive preoperative chemotherapy plus pembrolizumab is to continue to receive pembrolizumab for up to 27 weeks after surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation is as good as receiving pembrolizumab for 27 weeks after surgery in triple-negative breast cancer patients who achieved a pathologic complete response after preoperative treatment with chemotherapy and pembrolizumab.
Breast
III
Abramson, Vandana
NCT05812807
VICC-NTBRE23357
Sacituzumab Govitecan and Atezolizumab for the Prevention of Triple Negative Breast Cancer Recurrence
Breast
Breast
This phase II trial investigates how well sacituzumab govitecan and atezolizumab work in preventing triple negative breast cancer from coming back (recurrence). Atezolizumab is a protein that affects the immune system by blocking the PD-L1 pathway. The PD-L1 pathway controls the bodys natural immune response, but for some types of cancer the immune system does not work as it should and is prevented from attacking tumors. Atezolizumab works by blocking the PD-L1 pathway, which may help the immune system identify and catch tumor cells. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called SN-38. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers SN-38 to kill them. Giving sacituzumab govitecan and atezolizumab may work as a treatment for residual cancer in the breast or lymph nodes.
Breast
II
Abramson, Vandana
NCT04434040
VICCBRE2056
Talazoparib for the Treatment of BRCA 1/2 Mutant Metastatic Breast Cancer
Breast
Breast
This phase II trial studies how well talazoparib works for the treatment of breast cancer with a BRCA 1 or BRCA 2 gene mutation that has spread to other places in the body (metastatic). Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called poly (ADP-ribose) polymerases also called PARPs. PARPs are proteins that help repair deoxyribonucleic acid (DNA) mutations. PARP inhibitors, such as talazoparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become tumor cells. Tumor cells may be killed by a study drug, like talazoparib, that stops the normal activity of PARPs. Talazoparib may be effective in the treatment of metastatic breast cancer with BRCA1 or BRCA2 mutations.
Breast
II
Abramson, Vandana
NCT03990896
VICCBRE2265
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients with Advanced Triple-Negative Breast Cancer
Multiple Cancer Types
This phase Ib trial tests the safety and tolerability of ZEN003694 in combination with an immunotherapy drug called pembrolizumab and the usual chemotherapy approach with nab-paclitaxel for the treatment of patients with triple negative-negative breast cancer that has spread to other parts of the body (advanced). Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Immunotherapy with monoclonal antibodies, such as pembrolizumab may help the body's immune system attach the cancer and may interfere with the ability of tumor cells to grow and spread. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. Combination therapy with ZEN003694 pembrolizumab immunotherapy and nab-paclitaxel chemotherapy may help shrink or stabilize cancer for longer than chemotherapy alone.
Breast,
Phase I
I
Abramson, Vandana
NCT05422794
NCIBREP10525
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Breast
Breast
This open-label research study is studying (Z)-endoxifen as a possible treatment for
pre-menopausal (still having periods) women with ER+/HER2- breast cancer. (Z)-endoxifen is a
selective estrogen receptor modulator or "SERM." SERMs work to treat cancer by blocking the
body's natural estrogen from binding to cancer cells. This study includes a pharmacokinetic
part (PK, how the drug works in your body) and a treatment part. The primary purpose of the
study is to see how (Z)-endoxifen works on tumor cell growth by monitoring a cancer marker
called Ki-67. Ki-67 will be measured by biopsy of the breast after about 4 weeks of
treatment. If your cancer is responding to treatment based on the Ki-67 results, you may
continue treatment up to 24 weeks or until surgery.
The PK part of the study will be enrolled first, enrolling about 18 study participants who
will all receive oral once daily (Z)-endoxifen treatment. 12 of these participants will be
randomly assigned to treatment with an equal (50/50) chance to be assigned to (Z)-endoxifen
or (Z)-endoxifen + goserelin (a medication given to block the ovaries from making estrogen
and is also called ovarian suppression). This part of the study will help select the dose of
(Z)-endoxifen to use in the treatment part by measuring the levels of (Z)-endoxifen in the
blood stream and determine how long it takes for the body to remove it.
About 160 study participants will be enrolled in the treatment part. The treatment part will
help to determine how oral once daily (Z)-endoxifen, when taken by itself, compares to oral
once daily exemestane (a medication that decreases the amount of estrogen in the body, also
known as an aromatase inhibitor) and monthly injections of goserelin. Exemestane and
goserelin taken together is a standard treatment regimen for premenopausal patients with
ER+/HER2- breast cancer. Study participants are randomly assigned to treatment with an equal
(50/50) chance to be assigned to (Z)-endoxifen or standard treatment.
Study participation is up to 24 weeks of treatment followed by surgery.
pre-menopausal (still having periods) women with ER+/HER2- breast cancer. (Z)-endoxifen is a
selective estrogen receptor modulator or "SERM." SERMs work to treat cancer by blocking the
body's natural estrogen from binding to cancer cells. This study includes a pharmacokinetic
part (PK, how the drug works in your body) and a treatment part. The primary purpose of the
study is to see how (Z)-endoxifen works on tumor cell growth by monitoring a cancer marker
called Ki-67. Ki-67 will be measured by biopsy of the breast after about 4 weeks of
treatment. If your cancer is responding to treatment based on the Ki-67 results, you may
continue treatment up to 24 weeks or until surgery.
The PK part of the study will be enrolled first, enrolling about 18 study participants who
will all receive oral once daily (Z)-endoxifen treatment. 12 of these participants will be
randomly assigned to treatment with an equal (50/50) chance to be assigned to (Z)-endoxifen
or (Z)-endoxifen + goserelin (a medication given to block the ovaries from making estrogen
and is also called ovarian suppression). This part of the study will help select the dose of
(Z)-endoxifen to use in the treatment part by measuring the levels of (Z)-endoxifen in the
blood stream and determine how long it takes for the body to remove it.
About 160 study participants will be enrolled in the treatment part. The treatment part will
help to determine how oral once daily (Z)-endoxifen, when taken by itself, compares to oral
once daily exemestane (a medication that decreases the amount of estrogen in the body, also
known as an aromatase inhibitor) and monthly injections of goserelin. Exemestane and
goserelin taken together is a standard treatment regimen for premenopausal patients with
ER+/HER2- breast cancer. Study participants are randomly assigned to treatment with an equal
(50/50) chance to be assigned to (Z)-endoxifen or standard treatment.
Study participation is up to 24 weeks of treatment followed by surgery.
Breast
II
Abramson, Vandana
NCT05607004
VICCBRE22108
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study
Breast
Breast
Breast
III
Abramson, Vandana
NCT06492616
VICC-DTBRE24171